Therefore, we suggest that the high expression of IRAK3 contributes to maintaining the integrity of the BBB by inhibiting the Toll-like receptor and NF-κB pathways, thereby improving the prognosis of CM. The gene discussed is NFKB1; the disease is cutaneous mastocytosis.